Literature DB >> 2655543

Glucose intolerance after short-term administration of corticosteroids in healthy subjects. Prednisone, deflazacort, and betamethasone.

G Pagano1, A Bruno, P Cavallo-Perin, L Cesco, B Imbimbo.   

Abstract

Glucocorticoid-induced glucose intolerance has been related to the dose, duration of treatment, and steroid compound. However, a clear demonstration of this phenomenon is still lacking for fluorinated corticosteroids. We performed an oral glucose tolerance test in six healthy volunteers after the short-term administration of deflazacort (18 + 18 mg), prednisone (15 + 15 mg), and betamethasone disodium phosphate (1.5 + 1.5 mg) at equivalent anti-inflammatory doses, in random sequence, and in a triple crossover design. Fasting plasma glucose levels were not modified by deflazacort, whereas fasting plasma glucose levels together with insulin and C-peptide values were progressively and significantly increased by prednisone and betamethasone. During oral glucose tolerance testing a significant increase in the plasma glucose and insulin peaks was recorded after betamethasone and, to a lesser extent, after prednisone and deflazacort. These results suggest that betamethasone induces greater glucose intolerance and insulin resistance than prednisone and deflazacort.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2655543

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  17 in total

1.  Change in glucose metabolism after long-term treatment with deflazacort and betamethasone.

Authors:  A Bruno; G Pagano; L Benzi; G Di Ciani; V Spallone; G Calabrese; A Passeri
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Steroid differentiation: the safety profile of various steroids on retinal cells in vitro and their implications for clinical use (an American Ophthalmological Society thesis).

Authors:  Baruch D Kuppermann; Leandro Cabral Zacharias; M Cristina Kenney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

Review 3.  Post-transplant dyslipidemia: Mechanisms, diagnosis and management.

Authors:  Arnav Agarwal; G V Ramesh Prasad
Journal:  World J Transplant       Date:  2016-03-24

4.  Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action.

Authors:  Kevin C J Yuen; Patricia A McDaniel; Matthew C Riddle
Journal:  Clin Endocrinol (Oxf)       Date:  2012-08       Impact factor: 3.478

5.  The Canadian experience with long-term deflazacort treatment in Duchenne muscular dystrophy.

Authors:  Laura C McAdam; Amanda L Mayo; Benjamin A Alman; W Douglas Biggar
Journal:  Acta Myol       Date:  2012-05

6.  Deflazacort versus other glucocorticoids: a comparison.

Authors:  Surajit Nayak; Basanti Acharjya
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

7.  Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms.

Authors:  Cecilia P Chung; Annette Oeser; Joseph F Solus; Tebeb Gebretsadik; Ayumi Shintani; Ingrid Avalos; Tuulikki Sokka; Paolo Raggi; Theodore Pincus; C Michael Stein
Journal:  Arthritis Rheum       Date:  2008-07

Review 8.  Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk.

Authors:  Johannes M M Boots; Maarten H L Christiaans; Johannes P van Hooff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

9.  Serum glucose, insulin and C-peptide response to oral glucose after intravenous administration of hydrocortisone and methylprednisolone in man.

Authors:  A Bruno; P Carucci; M Cassader; P Cavallo-Perin; G Gruden; C Olivetti; G Pagano
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

10.  Disease activity, obesity, functional disability, and depression in patients with rheumatoid arthritis : Impact on lipid status, glycoregulation, and risk for coronary heart disease.

Authors:  P Ostojic; D Bartolovic
Journal:  Z Rheumatol       Date:  2016-09       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.